Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CpG 1018 in Early Alzheimer's Disease
NCT05606341Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CpG 1018 in Alzheimer's disease (AD) (4 arms), sponsored by NYU Langone Health. Primary endpoints: Number of Patient-Reported Adverse Events at 18 weeks, Percentage of Participants with Rheumatoid Factor at 18 weeks and 4 more. Started Mar 2023; status: recruiting.
02
Drugs
CpG 1018
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05606341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606341.